Intec Pharma (NTEC) Receives European Patent Related to Carbidopa/Levodopa Accordion Pill
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Intec Pharma Granted European Patent for Accordion Pill™–Carbidopa / Levodopa
September 6, 2016 7:30 AM EDTFortifies protection for Intec Pharma's leading product for Parkinson's disease currently in a global Phase III clinical trial
JERUSALEM--(BUSINESS WIRE)-- Intec Pharma Ltd. (Nasdaq: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announces that the European Patent Office has granted a European patent for an Accordion Pill containing certain drugs, including the combination Carbidopa and Levodopa. The patent, granted under No. 2276473, is titled Gastroretentive Drug Delivery for Carbidopa / Levodopa and is currently scheduled to remain in force until... More
